MEK and the inhibitors: from bench to bedside

@inproceedings{Akinleye2013MEKAT,
  title={MEK and the inhibitors: from bench to bedside},
  author={Akintunde R. Akinleye and Muhammad Mohsin Furqan and Nikhil Mukhi and Pavan Mahendra Ravella and Delong Liu},
  booktitle={Journal of hematology & oncology},
  year={2013}
}
Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with… CONTINUE READING